ICI combination was associated with significantly increased odds of colitis compared with conventional therapy (OR 32.06, 95% CrI 15.95 to 73.32), anti-PD-1/PD-L1 plus conventional therapy (OR 6.56, 95% CrI 2.81 to 16.16), and anti-PD-1 or anti-PD-L1 (OR 7.85, 95% CrI 4.67 to 14.49). Here, CD274 is linked to colitis.